Radiotherapy for Prostate Cancer

This trial tests two methods of delivering radiation therapy to men with prostate cancer to determine which causes fewer urinary and digestive side effects. One group receives a radiation boost to the entire prostate (prostate stereotactic body radiotherapy with whole gland boost), while the other group receives a boost to just the main tumor area (prostate stereotactic body radiotherapy with DIL boost). The trial seeks men with prostate adenocarcinoma who have not yet received treatment and have a specific type of lesion visible on an MRI scan. The primary goal is to identify the safer and more effective method. As a Phase 2, Phase 3 trial, this research measures treatment efficacy in an initial, smaller group and represents the final step before FDA approval, offering participants a chance to contribute to advancements in prostate cancer treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

In a previous study, patients who received a focused type of radiation therapy called prostate SBRT, with extra attention to the main tumor area, demonstrated that this treatment was feasible for most people. Research indicates that this method did not cause significant side effects for many patients, suggesting it is generally well-tolerated. Similarly, studies on SBRT targeting the entire prostate gland found the treatment safe and well-received by patients. Overall, both SBRT treatment methods have shown promising safety, with few reports of serious side effects.¹²³⁴⁵

Researchers are excited about these radiotherapy treatments for prostate cancer because they offer targeted approaches that could enhance effectiveness. Unlike traditional radiotherapy, which often treats the entire prostate gland uniformly, these methods use stereotactic body radiotherapy (SBRT) to deliver high-dose radiation precisely. Arm A focuses on boosting radiation directly to the prostate without a margin, while Arm B targets the dominant intra-prostatic lesion (DIL) with an even higher dose. This precision could potentially reduce side effects and improve outcomes, making these approaches promising advancements over existing treatments.

Research has shown that prostate stereotactic body radiotherapy (SBRT) is highly effective for treating prostate cancer. In this trial, participants will receive either a boost to the prostate alone or a boost to the dominant intra-prostatic lesion (DIL). For patients receiving extra radiation to the main tumor area within the prostate, one study found a 98.6% cure rate. This area often sees cancer recurrence, so targeting it can be crucial. For the entire prostate gland treatment with SBRT, studies have shown that about 95% of men remain cancer-free for at least five years post-treatment. Both methods have demonstrated promising results in improving survival rates and maintaining quality of life.²³⁴⁶⁷